Clinical trials · New York, NY
Allergy clinical trials in New York
We’re tracking 34 recruiting allergy studies with a site in or near New York — including Phase 1, Phase 1/Phase 2, Phase 2 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies near New York
- NCT06665646RecruitingPhase 1
HIV vaccine booster study for previous trial participants
This study tests a booster vaccine for HIV in people who were part of an earlier HIV vaccine trial. The goal is to see if it's safe and helps the immune system fight HIV better.
New York, New YorkAges 18–60 - NCT06056102RecruitingPhase 1
CAR-T cell therapy to help highly sensitized kidney transplant patients
This trial tests whether a special immune cell treatment (CAR-T cells) can lower the antibodies that make it very hard for you to receive a kidney transplant. If it works, you might become eligible for a transplant sooner.
New York, New YorkAges 18–65 - NCT03949855RecruitingPhase 2
Belimumab plus rituximab for primary membranous nephropathy
This study tests whether adding belimumab to rituximab helps people with primary membranous nephropathy (a kidney disease) that has the right blood test marker and specific protein levels. The goal is to improve kidney outcomes and reduce disease activity while keeping treatment safe.
New York, New YorkAges 18–75 - NCT06033196RecruitingPhase 2
Tocilizumab after lung transplant
This study tests whether the drug tocilizumab can help prevent your body from rejecting a new lung after transplant. It might help improve the success of your transplant by reducing immune system activity.
New York, New YorkAges 12–75 - NCT06476132RecruitingPhase 2
Belumosudil for lung transplant patients at risk of chronic rejection
This trial tests whether the drug Belumosudil can help prevent chronic lung rejection in people who recently had a lung transplant and showed signs of early rejection. It may improve long-term lung health.
New York, New YorkAges 12 years+ - NCT06796686RecruitingPhase 1
HIV vaccine safety and immune response study for healthy adults
This trial tests a new two-part HIV vaccine regimen in healthy adults without HIV. The goal is to see if it is safe and produces an immune response that could help prevent HIV.
New York, New YorkAges 18–55 - NCT05201469RecruitingPhase 2
VIB4920 for lupus kidney inflammation not responding well enough
This Phase 2 study tests VIB4920 to treat active lupus nephritis, a type of kidney disease caused by lupus. It may help reduce kidney inflammation and improve kidney outcomes in people with active disease despite standard care.
New York, New YorkAges 18 years+ - NCT07569029RecruitingPhase 1
HIV vaccine with treatment break to boost immune response
This Phase 1 trial tests two new HIV vaccines (DV700P-RNA and DV701B1.1-RNA) combined with a monitored break from HIV medications in people with well-controlled HIV. The goal is to see if this approach safely strengthens the immune system's ability to fight HIV.
New York, New YorkAges 18–60 - NCT06478017RecruitingPhase 2
Belatacept for heart transplant recipients
This study tests a drug called belatacept, which may help prevent the body from rejecting a new heart. It is given after a heart transplant, and the goal is to see if it works as well as or better than standard anti-rejection medicines.
New York, New YorkAges 18–76 - NCT04047628RecruitingPhase 3
MS patients with active relapsing disease comparing two treatment plans
This Phase 3 study compares the best standard MS treatment (chosen by your doctors) versus an approach called autologous hematopoietic stem cell transplant (AHSCT) for people with highly active, treatment-resistant relapsing multiple sclerosis. It aims to see which option controls MS disease activity better and keeps you safer over time.
New York, New YorkAges 18–55 - NCT05671757RecruitingPhase 1/Phase 2
Daratumumab for primary antiphospholipid syndrome
This early-phase study tests daratumumab, an immune-targeting drug, for people with primary antiphospholipid syndrome (APS). It aims to see whether it can reduce APS activity and improve outcomes while you continue your usual blood-thinning treatment.
New York, New YorkAges 18–65 - NCT07015996RecruitingPhase 2
Tezepelumab for peanut allergy oral immunotherapy
This trial tests whether adding tezepelumab (a biologic drug) to peanut oral immunotherapy can help people with peanut allergy better tolerate small amounts of peanut protein without having an allergic reaction.
New York, New YorkAges 12–55 - NCT07108387RecruitingPhase 2
Stopping or reducing tocilizumab for well-controlled giant cell arteritis
This study compares stopping tocilizumab (Actemra) completely versus reducing the dose in people whose giant cell arteritis has been well controlled for at least a year. The goal is to find out which approach keeps the disease in remission while reducing medication side effects.
New York, New YorkAges 50 years+ - NCT07778459Recruiting
Liver transplant study for people with HIV
This study tests whether it's safe and effective for people with HIV to receive a liver transplant from a donor who also has HIV. It aims to expand access to transplants for people with HIV.
New York, New YorkAges 18 years+ - NCT01186913Enrolling by invitation
Natural history study for severe combined immune deficiency (SCID)
This study follows children and adults with SCID and related immune disorders to understand how the illness behaves over time. It also helps researchers learn which testing results and genetic types of SCID match different treatment plans.
New York, New YorkAges Any age - NCT07279467Recruiting
Peanut allergy food challenge biomarker study
This study aims to identify markers in the blood that could help predict how severe a peanut allergy reaction might be. If you qualify, your child will undergo a supervised peanut challenge to see how their body responds.
New York, New YorkAges 1–17 - NCT06136091Recruiting
Asthma study in select communities using a smartphone app
This study looks at how asthma affects people in certain communities and tests a new way to manage it using a smartphone app. It is for people with long-standing asthma and those without asthma, to compare their health over time.
New York, New YorkAges 6–17 - NCT07220811RecruitingPhase 2
Testing a new drug for food allergies
This trial tests a new medication called RPT904 in people with IgE-mediated food allergies to foods like peanut, milk, egg, cashew, or walnut. The goal is to see if it reduces allergic reactions when you eat a small amount of the food.
New York, New YorkAges 12–55 - NCT06908083Enrolling by invitationPhase 1
Stopping HIV treatment with antibody therapy
This trial tests whether a combination of powerful antibodies (bNAbs) can help control HIV after stopping standard HIV treatment. Participants will pause their daily HIV medications while receiving these antibodies, and doctors will closely monitor their immune system and virus levels. It's for people who are already well-controlled on HIV treatment and have participated in a specific earlier study.
New York, New YorkAges 18–70 - NCT07768371RecruitingPhase 3
Remibrutinib for peanut, milk, or egg allergies
This study tests an investigational drug called remibrutinib to see if it can reduce allergic reactions to peanuts, milk, or eggs. It is for people aged 12 to 65 who have been diagnosed with a food allergy and are willing to participate in food challenges.
New York, New YorkAges 12–65 - NCT06504160RecruitingPhase 1
Testing a bacteria cream for eczema (TIME-2)
This study tests whether a cream made from a friendly skin bacteria (Staphylococcus hominis) can help treat eczema. Eligible participants will apply the cream to eczema patches on their arms, legs, or trunk for several weeks.
New York, New YorkAges 6 years+ - NCT07549503RecruitingPhase 2
Liver Transplant Immune Changes Study
This research study tracks early signs of immune system changes in children who received a liver transplant 3–7 years ago and are doing well. By studying blood and liver samples, researchers hope to better understand how to prevent rejection and improve long-term transplant survival.
New York, New YorkAges 3–13 - NCT06918990RecruitingPhase 1
CarBel for antibody-mediated rejection after kidney transplant
This study tests a new drug called CarBel to treat antibody-mediated rejection in kidney transplant patients. The goal is to see if it can help stop the rejection and protect your new kidney.
New York, New YorkAges 18–75 - NCT07390474RecruitingPhase 1
HIV vaccine safety and immune response study for healthy adults
This study tests two experimental mRNA-based HIV vaccines to see if they are safe and create an immune response. It is for healthy adults aged 18 to 55 who do not have HIV.
New York, New YorkAges 18–55
Hear when a new Allergy trial opens near New York, NY
We’ll email you when one opens near New York, NY — at most once a week, no account needed, unsubscribe anytime.
Allergy trials in other cities
Where these studies are running near New York
Institutions with a site for the recruiting allergy studies listed above.
- Northwell Health · 3 studies
- NYU Langone Health (Site # 71177) · 3 studies
- Columbia University Irving Medical Center · 2 studies
- Hospital for Special Surgery, New York: Division of Rheumatology · 2 studies
- Icahn School of Medicine at Mount Sinai / Mount Sinai Hospital · 2 studies
- Icahn School of Medicine at Mount Sinai: Department of Pediatrics Allergy & Immunology · 2 studies
- Columbia P&S CRS
- Columbia P&S CRS (Site ID: 30329)
What taking part in a allergy study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Looking wider? See all recruiting allergy studies in New York.
Common questions
- Are there allergy clinical trials near New York?
- Yes. We're currently tracking 34 recruiting allergy studies with a site near New York, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a allergy study near New York?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in New York to take part?
- Not necessarily. These studies have a site near New York, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a allergy trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New allergy studies open near New York regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.